SoftMedx Healthcare Limited has announced that trading in its shares on the Hong Kong Stock Exchange, suspended since 27 November 2017, will resume on 4 November 2025 at 9:00 a.m. for both the original counter (code: 648) and the temporary counter (code: 2906).

The suspension followed concerns raised by the Commission about a 9.9% purchase in New Ray Medicine International Holding Limited from a subsidiary of Town Health International Medical Group Limited. The Commission cited questions over the purchase price, the arm’s length nature of the transaction, and whether certain controlling influences were disclosed. The announcement also revealed civil proceedings under section 214 of the Securities and Futures Ordinance against several former directors and de facto directors, seeking their disqualification.

Following a joint internal control review conducted by BDO Risk Advisory Services Limited, the Company implemented recommendations to strengthen corporate governance, conflict of interest declarations, internal procedures for whistleblowing, approval processes for notifiable transactions, and more rigorous documentation of business performance reviews. The review concluded the current board and senior management are independent of previous controlling parties and have appropriate qualifications to manage the Group.

Having published the required announcements and undertaken to submit a follow-up review report, the Company has confirmed fulfilment of both the Stock Exchange’s and the Commission’s resumption conditions. Shareholders and potential investors are advised to exercise caution when dealing in the Company’s shares.